A trial using autologous BMMNCs showed greater clinical improvements in patients with Buerger’s disease in comparison with those with atherosclerotic PAD, and this was associated with greater EPC migration in response to VEGF in Buerger’s disease patients [33]. The gene discussed is VEGFA; the disease is peripheral arterial disease.